Azathioprine therapy for patients with systemic lupus erythematosus. 2001

M Abu-Shakra, and Y Shoenfeld
Rheumatic Diseases Unit and Department of Medicine D, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel.

Azathioprine is the only purine analog that is widely used for the management of systemic lupus erythematosus (SLE). For SLE patients without renal involvement, it is given to those patients who require a maintenance dose of 15 mg or higher of prednisone and for those who experience recurrent flares. Azathioprine in combination with steroids may be given to a large number of patients with lupus nephritis. It is also effective for patients with skin lesions, pneumonitis, thrombocytopenia or hemolytic anemia. Azathioprine may be used during pregnancy but not during lactation. It has not been shown to increase the risk for the development of malignancies among patients with SLE.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001379 Azathioprine An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) Azathioprine Sodium,Azathioprine Sodium Salt,Azathioprine Sulfate,Azothioprine,Immuran,Imuran,Imurel,Sodium, Azathioprine

Related Publications

M Abu-Shakra, and Y Shoenfeld
March 1973, Lancet (London, England),
M Abu-Shakra, and Y Shoenfeld
January 1975, Arthritis and rheumatism,
M Abu-Shakra, and Y Shoenfeld
April 1974, Harefuah,
M Abu-Shakra, and Y Shoenfeld
September 1966, Proceedings of the Royal Society of Medicine,
M Abu-Shakra, and Y Shoenfeld
January 1973, The New England journal of medicine,
M Abu-Shakra, and Y Shoenfeld
August 1978, JAMA,
M Abu-Shakra, and Y Shoenfeld
January 1990, Journal of internal medicine,
M Abu-Shakra, and Y Shoenfeld
January 1991, The New England journal of medicine,
Copied contents to your clipboard!